A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting

Phase 3 Completed 691 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.

Timeline

Start: 2002-08
Primary completion: —
Completion: 2004-06

Outcome

Met primary endpoint

paper Levofloxacin was as well tolerated and effective as standard-of-care antibiotics for the treatment of CAP in infants and children. PMID 17901791 ↗

Publications

Bradley JS, Arguedas A, Blumer JL, Saez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007 Oct;26(10):868-78. doi: 10.1097/INF.0b013e3180cbd2c7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levofloxacin	Small molecule	10 mg/kg	Intravenous